Abstract: The present invention concerns antibodies that react immunologically with anti-tumor antigen antibodies and compositions and methods related thereto. In particular, the antibodies that react immunologically with the anti-tumor antigen antibodies are employed in therapeutic, diagnostic, and prognostic embodiments related to cancer, including breast cancer, for example.

Abstract: The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.

Abstract: Novel thymidine kinase (TK1) derived peptide consisting of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 is employed to obtain ligands having specificity to the peptide. The ligand may be an antibody or fragment thereof and may be used in various methods and kits for health screening and the like.

Abstract: The present invention relates to combinations of biomarkers and levels thereof that may be used, for example, in the determination of risk associated with the occurrence of a major adverse cardiac event (MACE) in a patient.

Abstract: The invention relates to a method for the determination of an MRM or SRM assay for a protein of interest, a peptide of interest, or a group of proteins/peptides of interest or a whole proteome. It essentially includes the following steps: (1) a list of proteins of interest is selected and for each member at least one or a list of candidate proteotypic peptides is derived (2) this at least one peptide is synthesized/generated essentially without subsequent purification; (3) this at least one unpurified peptide is analyzed by selected reaction monitoring (SRM) preferably coupled to liquid chromatography (LC-SRM) or analogous techniques; (4) validation and/or optimisation of the corresponding assay of the at least one peptide with determination of the SRM coordinates for a peptide/protein of interest and/or of a regulator of interest is achieved.

Abstract: The present invention relates to the treatment of pulmonary diseases. More specifically, the invention relates to new methods of detecting and treating chronic obstructive pulmonary disease (COPD). In particular, the invention relates to a method of measuring one or more lipid metabolites in human body fluids as an indicator/biomarker of the progress of chronic obstructive pulmonary disease. The present invention also relates to a method of detecting and/or monitoring chronic obstructive pulmonary disease in a subject, the method comprising measuring the level of at least one lipid metabolite in a sample from the subject, wherein said level is indicative of COPD. The present invention also relates to a method of assessing the efficacy of a COPD treatment in a subject, the method comprising a step of measuring the level of at least one lipid metabolite in a sample from the subject, wherein said level is indicative of COPD severity or status.

Abstract: The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.

Abstract: The present invention provides CD4+ T-cell epitopes in bone morphogenetic proteins (BMPs). In particular embodiments, the present invention provides CD4+ T-cell epitopes of BMP-7 and BMP-14. In some preferred embodiments, the present invention provides CD4+ T-cell epitopes of BMP-7 and BMP-14 that are suitable for modification to reduce the immunogenicity of the BMP-7 and BMP-14 proteins.

Abstract: A method and apparatus for analyzing a sputum cytology preparation. The sputum sample is fixed on a microscope slide and analyzed by a microscope combined with an image acquisition system and a computer having an image recognition system. The image recognition system detects mobile cells that are implicated in the body's inflammatory response and counts how many of such cells are on the slide. The computer generates an absolute number of such cells and percentage values for such cells out the total number of mobile cells classified. The computer then utilizes the absolute numbers, the ratios of mobile cells with respect to each other—or a combination of both to generate a score. The score represents a probabilistic determination of inflammation.

Abstract: The invention describes a method for assaying HCV NS3 protease activity using an NS3•4A protease molecule. The invention also provides a method for screening and identifying modulators of NS3 protease.

Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.

Abstract: A single molecule detection platform is disclosed. The single molecule detection platform comprises a light-transmissive substrate, a plurality of spherical particles and a thin film. The surface of the light-transmissive substrate is etched to form a plurality of cone-shaped structures. Each spherical particle is disposed on top of each cone-shaped structure. The sizes of the plurality of spherical particles are suitable to allow only a single protein to be attached to each spherical particle. The thin film is deposited on the surface of the plurality of cone-shaped structures and acts as a reflective layer of one-dimensional waveguide. The plurality of spherical particles is not covered by the thin film.

Abstract: A method for quantitatively analyzing an anticoagulant in a sample may include: (a) providing and incubating a reaction mixture comprising (i) the sample, (ii) a defined amount of an activated coagulation factor whose activity is directly or indirectly influenceable by the anticoagulant to be determined, wherein the activated coagulation factor is present in a separate reagent which is added to the reaction mixture, (iii) a cleavable substrate which has at least one cleavage site for the activated coagulation factor, and (iv) a solid phase to which the cleavable substrate is bound or becomes bound during the incubation; (b) separating the solid phase; and (c) determining the amount of solid-phase-bound, uncleaved substrate, wherein the determined amount of the solid-phase-bound uncleaved substrate is proportional to an amount or activity of the anticoagulant in the sample.

Abstract: The invention relates to a method for analysing ingredients, in particular lipids and/or vitamins and biological material ingredients, to methods of using relevant organic solvents or organic solvent mixtures, and to a spectrophotometer for measuring biological material ingredients. It is proposed to treat the biological materials with at least one organic solvent which extracts the ingredients, to convert the bi ological materials to a solidified form during the extraction, with the result that a solidified sediment and a liquid organic phase as the supernatant are formed, and to examine the extracted ingredients in the supernatant.

Abstract: Natural and synthetic compounds of Formulae Ia-Ie having a lactone structure, in particular Securolide, have been determined to be effective anti-tumor compounds which target the hrad9 gene and/or protein encoded thereby or complex containing the protein and/or the p53 gene and/or protein. Securolide is cytoselective for mutants of hRad9 based on studies conducted in Rad9 mutant yeast strains. Securolide appears to interact with mutant hRad9 in cancer cells to produce DNA lesions which result in apoptosis. Studies have demonstrated that Securolide is useful for treating proliferation disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer, and to alleviate pain associated with the cancer.

Abstract: Ligand-capped nanoparticles are dispersed in an organic solvent. There is then phase transfer of the nanoparticles introducing into the organic solvent an aqueous solution of polymer surfactant dissolved in water. The organic solvent and the aqueous solution are then mixed until the polymer forms micelles which encapsulate the nanoparticles in assemblies. The resultant nanoparticle assemblies in an aqueous phase may be used for any of a range of desired applications. It has been found that the assembly size can be tuned by control of any or a combination of method parameters such as concentration of polymer surfactant, and/or temperature of the phase change reaction, and/or rate of mixing, such as rotational rate of stirring. The nanoparticle assemblies find particular application as fluorescent biomarkers.

Abstract: The present invention relates to a non-toxic dipolar solvent for chromogenic substrate for detecting presence of lacZ gene and/or gene activity, which comprises a stabilizing amount of a solubilizing agent. The present invention also relates to a method for inducing lac operon in screening assay, comprising the step of contacting an agar plate with at least one essential oil in a concentration sufficient to induce the lac operon. The present invention further relates to a method for detecting the presence of bacteria, comprising the step of contacting an agar plate with at least one essential oil in a concentration sufficient to induce detection of the bacteria.

Abstract: Systems and methods of sample (1) and staining processing including compression and dynamic movement of liquids (3) in a fluidically moving substantially contained liquid bridge (6) perhaps between a hydrophobic wand (4) and a hydrophilic sample support element (2). Embodiments may include low volume reagent and perhaps even low volume buffer wash in sample processing. In addition, antibodies can be conjugated with nanoparticles (64) and can be used in sample processing. Exposing a sample with or without movement to AC, DC, or even a permanent magnet field may improve staining. Staining with nanoparticle reagents could be quantified using a microscope with a magnetometer below the slide viewing area. The detection of nanoparticles attached to the chemistry may facilitate the quantification of cancerous cells stained in the tissue.

Abstract: A process for maintaining 3 dimensional orientation between a tissue specimen and images of the area of investigation, to register histopathologic diagnoses of multiple locations within the specimen with corresponding locations on the surface of said area of investigation.

Abstract: Disclosed is a method for the preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester, comprising the asymmetric reduction of arylketone and the carbamation of alcohol.

Abstract: The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation.

Abstract: A method is described for producing protein compositions having reduced amounts of O-linked glycosylation. The method includes producing the protein in cells cultured in the presence of an inhibitor of Pmt-mediated O-linked glycosylation and/or in the presence of one or more ?-1,2-mannosidases.

Abstract: The invention relates to a method for producing biologically active ?-NGF from the proform proNGF. After expressing the proform of the ?-NGF in a prokaryotic host cell, the recombinant protein is isolated in the form of insoluble inactive aggregates (inclusion bodies). After the solubilization thereof in a strong denaturing agent and the subsequent conversion thereof into the natural conformation, which is determined by the disulfide bridges present in the natural ?-NGF, biologically active ?-NGF is obtained by subsequently splitting-off the prosequence.

Abstract: A fibrillation-resistant insulin analogue may be a single-chain insulin analogue or a physiologically acceptable salt thereof, containing an insulin A chain sequence or an analogue thereof and an insulin B chain sequence or an analogue thereof connected by a polypeptide of 4-10 amino acids. The fibrillation-resistant insulin analogue preferably displays less than 1 percent fibrillation with incubation at 37° C. for at least 21 days. A single-chain insulin analogue displays greater in vitro insulin receptor binding than normal insulin while displaying less than or equal binding to IGFR than normal insulin. The fibrillation-resistant insulin may be used to treat a patient using an implantable or external insulin pump, due to its greater fibrillation resistance.

Abstract: The current inventors have discovered that the incorporation of a triplex forming monomer unit into oligonucleotides surprisingly gives the oligonucleotide a number of favorable characteristics. The oligonucleotides are advantageous because they allow modulation of the melting temperature of an oligonucleotide, they have improved sequence specificity and they can form triplexes by Hoogsteen or reverse Hoogsteen base pairing with double stranded nucleic acids. Moreover, some of the oligonucleotides of the invention have useful fluorescent characteristics, and the oligonucleotides comprising a triplex forming monomer can be used as substrates for enzymatic manipulations such as primer extension.

Abstract: A method is disclosed for the determination of 5-ASA efficacy in preventing and/or treating CRC in a mammalian, which comprises the analysis of the inhibition of the ?-catenin pathway in presence of 5-ASA. More in details, the method comprises measuring the expression of at least one gene involved in the regulation of the ?-catenin signalling pathway, such as ?-protocadherin, E-cadherin, ?-catenin, Axin1, ICAT, p21waf?1 and the expression of onco-suppressor genes, such as KLF4 and CEBP?. Gene expression can be measured in accordance to the methods commonly available in the art such as QRT-PCR and immunohistochemistry.

Abstract: The present invention provides an efficient way for high throughput haplotype analysis. Several polymorphic nucleic acid markers, such as SNPs, can be simultaneously and reliably determined through multiplex PCR of single nucleic acid molecules in several parallel single molecule dilutions and the consequent statistical analysis of the results from these parallel single molecule multiplex PCR reactions results in reliable determination of haplotypes present in the subject. The nucleic acid markers can be of any distance to each other on the chromosome. In addition, an approach wherein overlapping DNA markers are analyzed can be used to link smaller haplotypes into larger haplotypes. Consequently, the invention provides a powerful new tool for diagnostic haplotyping and identifying novel haplotypes.

Abstract: The invention provides a process for the production of lipase inhibitors via an improvised fermentation process characterized in that a combinatorial feeding of linoleic acid or its esters or salts thereof and an omega-9 fatty acid, preferably oleic acid and/or its derivatives is employed during said process resulting in an improved yield co-efficient, productivity further providing ease of operation.

Abstract: An object of the present invention is to provide a method for efficiently producing an oligomer or a monomer by degrading a biodegradable resin using an enzyme, so that the oligomer or the monomer can be recovered. The present invention provides a method for producing an oligomer and/or a monomer by degrading a biodegradable resin in a degradation liquid containing a biodegradation enzyme, a buffer agent, an organic solvent, and water. In this method, the SP value of the organic solvent is less than 8.5 or more than 11.5, and the percentage content of the organic solvent (by volume) in the degradation liquid is higher than 1% and lower than 15%. In the method for producing an oligomer or a monomer, the degradation percentage of the biodegradable resin is low, and deposits of aggregates of the oligomer and/or the monomer are few, so that the recovery percentage is high.

Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Abstract: The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention.

Abstract: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.

Abstract: The invention provides nitrilases and methods for making and using them, and in one aspect, provides methods for producing enantiomerically pure ?-substituted carboxylic acids, such as, for example, ?-amino acids and ?-hydroxy acids. In one aspect, methods of the invention combine an aldehyde or ketone with a cyanide and ammonia or an ammonium salt or an amine, in the presence of a nitrilase or a polypeptide having nitrilase activity, to stereoselectively hydrolyze the amino nitrile or cyanohydrin intermediate under conditions sufficient to produce the carboxylic acid.

Abstract: Fatty acid 13-hydroperoxide lyase proteins which have been modified with respect to a previously described guava 13-hydroperoxide lyase and the nucleic acid sequences encoding these proteins. Also, recombinant nucleic acid molecules for expressing the modified 13-hydroperoxide lyases and methods of using such lyases in the field of organic synthesis.

Abstract: Liquid bacteriophage products may be dried to form dry bacteriophage products. Drying may be effected by pulse combustion drying processes. When dried, the number of viable bacteriophage particles is reduced by no more than about two log (102). The resulting dry bacteriophage product, therefore includes at least one percent of the number of viable bacteriophage particles that were present in the original liquid bacteriophage product.

Abstract: Methods and compositions for cloning a donor DNA molecule into an acceptor vector at a predetermined location are described. The methods are based on homologous recombination mediated by in vitro treatment of the donor DNA and the acceptor vector with an enzyme cocktail containing an exonuclease and a single-stranded DNA binding protein.

Abstract: Methods and materials related to producing 3-HP as well as other organic compounds are disclosed. Specifically, isolated nucleic acids, polypeptides, host cells, and methods and materials for producing 3-HP and other organic compounds are disclosed.

Abstract: A method for making at least 2 kg (dry weight) of a lactic acid bacteria composition formulated with from 1% to 50% of ascorbate or ascorbic acid (w/w?dry matter) as antioxidant, wherein the pH is controlled so 3?pH?8 during at least the majority of the fermentation process by addition of a base not comprising NH3 (ammonia).

Abstract: A medium for enriching Listeria spp. without polymerase chain reaction (PCR) inhibition and a method of using the medium.

Abstract: An isolated fungus is described. The isolated fungus produces at least one compound selected from the group consisting of 1,8-cineole, 1-methyl-1,4-cyclohexadiene, and (+)-?-methylene-?-fenchocamphorone. A method for producing at least one compound selected from the group consisting of 1,8-cineole, 1-methyl-1,4-cyclohexadiene, and (+)-?-methylene-?-fenchocamphorone is also described. The method includes culturing a fungus on or within a culturing media in a container under conditions sufficient for producing the at least one compound.

Abstract: High-throughput detection for the interesting base or the mutation site in the nucleic acid sample can be achieved by means of the linear test probe pairs P1 and P2. The test probe pairs P1 and P2 respectively comprise either of the flanking complementary sequences which are adjacent to the interesting base or the mutation site in the nucleic acid sample. The invention can be applied to the re-sequencing the target nucleic acid sequence, the detection and analysis for the mutation, insertion, or deletion sites of a known nucleic acid sequence, and the genotyping of the pathogenic microorganism.

Abstract: The present invention is in the field of cell bioreactors, and specifically in the field of disposable bioreactors.

Abstract: An automated analyzer for performing multiple diagnostic assays simultaneously includes multiple stations in which discrete aspects of the assay are performed on fluid samples contained in sample vessels. The analyzer includes stations for automatically preparing a sample, incubating the sample, preforming an analyte isolation procedure, ascertaining the presence of a target analyte, and analyzing the amount of a target analyte. An automated receptacle transporting system moves the sample vessels from one station to the next. A method for performing an automated diagnostic assay includes an automated process for isolating and amplifying a target analyte, and, in one embodiment, a method for real-time monitoring of the amplification process.

Abstract: An assembly comprises a multiwell test plate having a plurality of wells having an opening and a base surface, an insert plate having a plurality of inserts positioned to align with a corresponding one of the wells whereby the insert plate can be nested with the multiwell plate. Each of the inserts includes a supply port arranged for flow communication with a supply source, an exhaust port, a bottom portion having a plurality of channels extending between the supply port and the exhaust port, and a gas permeable membrane covering the bottom portion. Each of the inserts is sized to position the gas permeable membrane a desired distance from the base surface of the multiwell test plate when the multiwell test plate and the insert plate are coupled to one another.

Abstract: Described herein are methods for producing chemical products by anaerobically fermenting a particular biomass using anaerobic bacteria. Such chemical products include hydrogen and other gases, acetic acid and other volatile organic acids, solvents, solids, and salts of volatile organic acids.

Abstract: It is described a bidirectional promoter for expression of at least two coding sequences in opposite direction in animal cells; bidirectional expression cassettes; expression constructs; gene transfer expression vectors, and methods for the use thereof.

Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.

Abstract: The present invention relates to a herpes virus vector which comprises a modified genomic sequence encoding a microRNA (miRNA) against a target sequence. The herpes virus vector may be used as or in a vaccine to prevent and/or treat a disease.

Abstract: Cultures of cells immunoreactive for glial fibrillary acidic protein (GFAP), as well as for the intermediate filament marker nestin were grown in a medium including epidermal growth factor (EGF) and serum. The cultured cells had the morphology of astroglial cells. The cells can be proliferated in adherent or suspension cultures. Depending on the culture conditions, the cells can be induced to differentiate to neurons or glial cells. The cultures can be expanded over a large number of passages during several months, and survive, express an astroglial phenotype and integrate well after transplantation into both neonatal and adult rat forebrain.

Abstract: A versatile compartmentalized cell culture device, with a selectively permeable membrane separating the compartments, provides many attributes relative to traditional devices. It can be configured for high-density cell culture, co-culture, and sample dialysis while rolling or standing still. It can also be configured for continuous movement of liquid between compartments. The wide combination of attributes not found in other membrane based cell culture and bioprocessing devices includes more cell capacity, more cell secreted product capacity, higher cell and product density, increased medium capacity, minimized use of exogenous growth factors, compatibility with standard cell culture equipment and protocols, increased scale up efficiency, capacity to function when rolling or standing still, capacity for perfusion without the need for pumps, and more efficient sample dialysis.